DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1P29S mutation
Highlights: • A guanine nucleotide exchange factor DOCK1 promotes GDP/GTP exchange of Rac1{sup P29S}. • DOCK1 deficiency cancels Rac1{sup P29S}-mediated invasion and macropinocytosis. • A DOCK1 inhibitor suppresses Rac1{sup P29S}-mediated invasion and macropinocytosis. Rac1 is a member of the Rho family of small GTPases that regulates cytoskeletal reorganization, membrane polarization, cell migration and proliferation. Recently, a self-activating mutation of Rac1, Rac1{sup P29S}, has been identified as a recurrent somatic mutation frequently found in sun-exposed melanomas, which possesses increased inherent GDP/GTP exchange activity and cell transforming ability. However, the role of cellular Rac1-interacting proteins in the transforming potential of Rac1{sup P29S} remains unclear. We found that the catalytic domain of DOCK1, a Rac-specific guanine nucleotide exchange factor (GEF) implicated in malignancy of a variety of cancers, can greatly accelerate the GDP/GTP exchange of Rac1{sup P29S}. Enforced expression of Rac1{sup P29S} induced matrix invasion and macropinocytosis in wild-type (WT) mouse embryonic fibroblasts (MEFs), but not in DOCK1-deficient MEFs. Consistently, a selective inhibitor of DOCK1 that blocks its GEF function suppressed the invasion and macropinocytosis in WT MEFs expressing Rac1{sup P29S}. Human melanoma IGR-1 and breast cancer MDA-MB-157 cells harbor Rac1{sup P29S} mutation and express DOCK1 endogenously. Genetic inactivation and pharmacological inhibition of DOCK1 suppressed their invasion and macropinocytosis. Taken together, these results indicate that DOCK1 is a critical regulator of the malignant phenotypes induced by Rac1{sup P29S}, and suggest that targeting DOCK1 might be an effective approach to treat cancers associated with Rac1{sup P29S} mutation.